C‐code for Lilly Oncology Drug

Eli Lilly and Company announce the assignment of a product‐specific C‐code for Portrazza® (necitumumab) injection.  The Centers for Medicare & Medicaid Services (CMS) released the April 2016 Update of the Hospital Outpatient Prospective Payment System (OPPS), which included designation of C9475 for Portrazza with the effective date of April 1, 2016.1

Trade Name HCPCS Code Strength NDC CMS Long Descriptor Effective Date
Portrazza C9475 800 mg/50 mL (16 mg/mL) 00002-7716-01* Injection, necitumumab, 1mg April 1, 2016

*Note that the product’s NDC code has been “zero‐filled” to ensure creation of an 11‐digit code that meets CMS standards.

The zero‐fill location is indicated in bold.

HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code.

Portrazza was approved by the US Food and Drug Administration on November 24, 2015. Portrazza is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Portrazza is not indicated for the treatment of nonsquamous NSCLC.

No comments have been posted yet.